• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Sokolow Leonard J

    6/28/24 8:53:50 PM ET
    $VVOS
    Medical/Dental Instruments
    Health Care
    Get the next $VVOS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    SOKOLOW LEONARD J

    (Last) (First) (Middle)
    7921 SOUTHPARK PLAZA,
    SUITE 210

    (Street)
    LITTLETON CO 80120

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Vivos Therapeutics, Inc. [ VVOS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    06/20/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $2.38 06/20/2024 A 4,000 (1) 06/20/2029 Common Stock 4,000 $2.38 7,467 D
    Explanation of Responses:
    1. On June 20, 2024, the Reporting Person received a grant of 4,000 stock options from the Issuer. One-half vested immediately, one-fourth will vest on September 30, 2024 and one-fourth will vest on December 31, 2024.
    /s/ Bradford K. Amman as attorney-in-fact for Leonard J. Sokolow 06/28/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VVOS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VVOS

    DatePrice TargetRatingAnalyst
    8/13/2021$11.00 → $10.00Buy
    Roth Capital
    More analyst ratings

    $VVOS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

      Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults, and moderate to severe OSA in childr

      5/15/25 4:20:00 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

      LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on May 15, 2025 to review the results and provide an overview of the

      5/14/25 9:15:00 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Signs Definitive Agreement to Acquire Largest Sleep Center Operator in Nevada

      By acquiring The Sleep Center of Nevada, Vivos expands its business model to make its OSA treatments available to thousands of patients in the greater Las Vegas metro area Acquisition expected to close later this quarter or in the third quarter LITTLETON, Colo., April 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in proprietary, non-invasive treatments for obstructive sleep apnea (OSA), today announced a definitive agreement to acquire the operating assets of The Sleep Center of Nevada ("SCN"), the largest operator of medical sleep centers in Nevada. Significant Vivos investor New Seneca Partners, Inc., a leading Nor

      4/16/25 8:30:00 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Financials

    Live finance-specific insights

    See more
    • Vivos Therapeutics Reports First Quarter 2025 Financial Results and Provides Operational Update

      Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults, and moderate to severe OSA in childr

      5/15/25 4:20:00 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Schedules Release of First Quarter 2025 Financial Results and Conference Call

      LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on May 15, 2025 to review the results and provide an overview of the

      5/14/25 9:15:00 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Reports Full Year 2024 Financial Results and Provides Operational Update

      Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults) and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the full year ended D

      3/31/25 4:20:00 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Executive Officer Huntsman Ronald Kirk

      4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

      11/27/24 4:47:13 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Amman Bradford K.

      4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

      11/27/24 4:43:54 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Sokolow Leonard J

      4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)

      6/28/24 8:53:50 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

      Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $10.00 from $11.00 previously

      8/13/21 1:08:07 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Roth Capital reiterated coverage on Vivos Therapeutics with a new price target

      Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $11.00 from $12.00 previously

      5/18/21 10:44:01 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care

    $VVOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $VVOS
    SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

      SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

      11/14/24 4:49:30 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vivos Therapeutics Inc.

      SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)

      11/14/24 4:05:24 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Vivos Therapeutics Inc.

      SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)

      9/24/24 2:59:09 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

      8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

      6/6/25 5:19:55 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

      5/23/25 8:00:22 AM ET
      $VVOS
      Medical/Dental Instruments
      Health Care
    • Vivos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)

      5/15/25 5:25:05 PM ET
      $VVOS
      Medical/Dental Instruments
      Health Care